IVERIC bio Inc (ISEE)

15.165
+0.005(+0.03%)
  • Volume:
    1,110,656
  • Day's Range:
    15.040 - 15.630
  • 52 wk Range:
    8.850 - 20.990

ISEE Overview

Prev. Close
15.16
Day's Range
15.04-15.63
Revenue
-
Open
15.12
52 wk Range
8.85-20.99
EPS
-1.23
Volume
1,110,656
Market Cap
1.82B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,460,592
P/E Ratio
-9.30
Beta
1.52
1-Year Change
-7.39%
Shares Outstanding
118,077,814
Next Earnings Date
Nov 08, 2022
What is your sentiment on IVERIC bio?
or
Vote to see community's results!

IVERIC bio Inc Analysis

IVERIC bio Inc Company Profile

IVERIC bio Inc Company Profile

Employees
94

IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

Read More

Analyst Price Target

Average24.000 (+58.00% Upside)
High30
Low12
Price15.19
No. of Analysts11
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellBuyBuy
Technical IndicatorsNeutralStrong BuyStrong SellStrong SellStrong Buy
SummaryNeutralNeutralStrong SellNeutralStrong Buy
  • over reacting , let's wait for Monday
    1
    • If this gets to 5.00$ or above and holds there, it might look like Arrowhead Pharmaceuticals. ARWR. Any thoughts?
      1
      • the treatments they are researching are very rare and R&D is very high. so I don't know how much of an earning potential they can get even if they do successful make a treatment.
        0
    • wow this stock was the hottest yesterday and only the first reply in 2 years... I see other stocks / futures have very active discussions...
      1
      • 9
        0
    • think 4.58 then 32.00 maybe
      1
      • Very cool. ..back to $40?
        0
        • q3 erning most important data IS total stockholders equity is POSITIV!!!!
          0